| Field | Row 1 |
|---|---|
| adsh | 0001606498-25-000091 |
| cik | 1606498 |
| name | AVANOS MEDICAL, INC. |
| sic | 3842 |
| countryba | US |
| stprba | GA |
| cityba | ALPHARETTA |
| zipba | 30004 |
| bas1 | 5405 WINDWARD PARKWAY |
| bas2 | SUITE 100 SOUTH |
| baph | 844-428-2667 |
| countryma | US |
| stprma | GA |
| cityma | ALPHARETTA |
| zipma | 30004 |
| mas1 | 5405 WINDWARD PARKWAY |
| mas2 | SUITE 100 SOUTH |
| countryinc | US |
| stprinc | DE |
| ein | 464987888 |
| former | AVANOS MEDICAL, INC. |
| changed | 20180702 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250506 |
| accepted | 2025-05-06 16:18:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | avns-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001606498-25-000091 | 20250331 | Accounts Payable Current | 46000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Accrued Liabilities Current | 91300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -44600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 107700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Common Stock Value | 500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Deferred Income Tax Liabilities Net | 5500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Earnings Per Share Diluted | -0.0200 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Earnings Per Share Diluted | 0.1400 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Gain Loss On Disposition Of Assets1 | -200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Income Loss From Continuing Operations | 500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 9700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Increase Decrease In Accrued Liabilities | -27600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Increase Decrease In Inventories | 4700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 112300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Cash Provided By Used In Financing Activities | -700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Cash Provided By Used In Operating Activities | -8000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | 300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | -100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Liabilities Noncurrent | 4500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20230930 | Proceeds From Divestiture Of Businesses | 110000000.0000 | USD | 0 | us-gaap/2024 | Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= R H Business; | ||
| 0001606498-25-000091 | 20240331 | Proceeds From Divestiture Of Businesses | 2100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Property Plant And Equipment Net | 109800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 94600000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 15200000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Corporate Other; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 167500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 101100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 24500000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Surgical Pain And Recovery; | ||
| 0001606498-25-000091 | 20240331 | Selling General And Administrative Expense | 83600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Share Based Compensation | 3800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | 500000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | -707000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | 500000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001606498-25-000091 | 20241231 | Assets | 1154200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Assets | 1107800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Assets Current | 393400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Cost Of Goods And Services Sold | -31200000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Cost Of Goods And Services Sold | -20700000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Loss From Continuing Operations | 6600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 1500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Increase Decrease In Accounts Payable Trade | -6400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 107200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Inventory Net | 138100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Liabilities | 325700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Liabilities | 268400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Income Loss | 13300000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Net Income Loss | 6600000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20241231 | Operating Lease Liability Noncurrent | 24600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Payment For Contingent Consideration Liability Financing Activities | 500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Payments For Repurchase Of Common Stock | 9100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Proceeds From Divestiture Of Businesses | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Proceeds From Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Repayments Of Lines Of Credit | 2300000.0000 | USD | 1 | us-gaap/2024 | Credit Facility= Term Loan Facilities; Longterm Debt Type= Unsecured Debt; | ||
| 0001606498-25-000091 | 20240331 | Repayments Of Secured Debt | 1600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 166100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 150900000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 157400000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 26600000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Neonate Solutions; | ||
| 0001606498-25-000091 | 20231231 | Stockholders Equity | 1663600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | -315800000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | 828500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Treasury Stock Value Acquired Cost Method | 6700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | 0.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | 400000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001606498-25-000091 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 400000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20240331 | Cost Of Goods And Services Sold | 71300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -42300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Additional Paid In Capital | 1678600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 3800000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Assets Current | 352400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 107700000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001606498-25-000091 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -11900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Common Stock Shares Outstanding | 45962627.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Common Stock Shares Outstanding | 46236444.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Common Stock Value | 500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Depreciation Depletion And Amortization | 9600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | -0.0300 | USD | 1 | us-gaap/2024 | Disposal Group Classification= Discontinued Operations Held For Sale Or Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= R H Business; | ||
| 0001606498-25-000091 | 20240331 | Gain Loss On Disposition Of Assets1 | -300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Goodwill | 455600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Goodwill | 327600000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; | ||
| 0001606498-25-000091 | 20240331 | Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | -1400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Interest Expense Nonoperating | 3100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Interest Expense Nonoperating | 2100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Liabilities Current | 137200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Cash Provided By Used In Operating Activities | 25700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Income Loss | 21300000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Other Assets Noncurrent | 25400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -2500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 2300000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 2300000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001606498-25-000091 | 20241231 | Other Liabilities Noncurrent | 4400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Proceeds From Lines Of Credit | 20000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Proceeds From Stock Options Exercised | 500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Proceeds From Stock Options Exercised | 400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Repayments Of Lines Of Credit | 25000000.0000 | USD | 1 | us-gaap/2024 | Credit Facility= Revolving Credit Facility; Longterm Debt Type= Unsecured Debt; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 15200000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Corporate And Other; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 94600000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Specialty Nutrition Systems; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 56300000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 74500000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Enteral Feeding; | ||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | -95000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | 300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | 1678600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | 839400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Accounts Payable Current | 54300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Accounts Receivable Net | 104800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -10700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001606498-25-000091 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Cost Of Goods And Services Sold | 77700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | -0.0300 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | -0.0300 | USD | 1 | us-gaap/2024 | Disposal Group Classification= Discontinued Operations Held For Sale Or Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= R H Business; | ||
| 0001606498-25-000091 | 20241231 | Goodwill | 327600000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; | ||
| 0001606498-25-000091 | 20240331 | Income Loss From Continuing Operations | 1500000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Income Loss From Continuing Operations Per Basic Share | 0.0100 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Income Loss From Continuing Operations Per Diluted Share | 0.0100 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Increase Decrease In Accounts Receivable | -25100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Liabilities And Stockholders Equity | 1154200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Long Term Debt | 125300000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Income Loss | 21100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Operating Income Loss | 4000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Operating Lease Right Of Use Asset | 34100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Other Assets Noncurrent | 23200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Operating Activities Cash Flow Statement | 100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Payments To Acquire Productive Assets | 4100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Repayments Of Lines Of Credit | 10000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Repayments Of Secured Debt | 2300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Retained Earnings Accumulated Deficit | -707000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 70000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Enteral Feeding; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 56300000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Pain Management And Recovery; | ||
| 0001606498-25-000091 | 20250331 | Selling General And Administrative Expense | 75700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | 1227900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | -44600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20240331 | Treasury Stock Value Acquired Cost Method | 9100000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20241231 | Accounts Receivable Net | 132800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Accrued Liabilities Current | 71400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 3600000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Cash And Cash Equivalents At Carrying Value | 97000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 75800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 97000000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001606498-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 97000000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001606498-25-000091 | 20241231 | Deferred Income Tax Assets Net | 24900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Earnings Per Share Basic | 0.1400 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Goodwill | 128300000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pain Management And Recovery; | ||
| 0001606498-25-000091 | 20240331 | Gross Profit | 94800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Loss From Continuing Operations | 9700000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Income Tax Expense Benefit | 1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Increase Decrease In Accounts Payable Trade | 2300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Interest Expense Nonoperating | 2500000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20241231 | Inventory Net | 138800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Investment Income Interest | 600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Investment Income Interest | 1500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Long Term Debt Current | 9400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 2300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -100000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001606498-25-000091 | 20250331 | Payments For Proceeds From Investments In Non Affiliates | 2400000.0000 | USD | 1 | 0001606498-25-000091 | |||
| 0001606498-25-000091 | 20250331 | Preferred Stock Shares Authorized | 20000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Prepaid Expense And Other Assets Current | 12500000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 27000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Surgical Pain And Recovery; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 31700000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Radiofrequency Ablation; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 101100000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Specialty Nutrition Systems; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | -44900000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001606498-25-000091 | 20241231 | Stockholders Equity | -99000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | -100000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | -42300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | -700400000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | -101200000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 500000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Treasury Stock Value Acquired Cost Method | 2200000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20240331 | Cost Of Goods And Services Sold | -20300000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Cost Of Goods And Services Sold | -35200000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | -0.0300 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | -1400000.0000 | USD | 1 | us-gaap/2024 | Disposal Group Classification= Discontinued Operations Held For Sale Or Disposed Of By Sale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= R H Business; | ||
| 0001606498-25-000091 | 20250331 | Long Term Debt | 98000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Income Loss | -2100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Net Income Loss | 6600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Income Loss | 200000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Operating Lease Liability Current | 10400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Operating Lease Liability Noncurrent | 23100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Operating Lease Right Of Use Asset | 32100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | -100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 100000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001606498-25-000091 | 20250331 | Other Operating Income Expense Net | 1600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Payment For Contingent Consideration Liability Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Payments For Proceeds From Investments In Non Affiliates | 0.0000 | USD | 1 | 0001606498-25-000091 | |||
| 0001606498-25-000091 | 20241231 | Prepaid Expense And Other Assets Current | 14100000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Repayments Of Lines Of Credit | 25000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Research And Development Expense | -4200000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Research And Development Expense | -1100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 56300000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 24600000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Neonate Solutions; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 10200000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Corporate Other; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 56200000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Pain Management And Recovery; | ||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | 1667700000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | -42600000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001606498-25-000091 | 20250331 | Stockholders Equity | 1682800000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001606498-25-000091 | 20250331 | Additional Paid In Capital | 1682800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 87700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 107700000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001606498-25-000091 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001606498-25-000091 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Deferred Income Tax Assets Net | 25000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Deferred Income Tax Liabilities Net | 5600000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -1200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Increase Decrease In Accrued Liabilities | -14800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Increase Decrease In Inventories | -1200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Interest Expense Nonoperating | 600000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Liabilities And Stockholders Equity | 1107800000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Cash Provided By Used In Investing Activities | -9100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Income Loss | -900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Operating Income Loss | 10300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 2300000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Preferred Stock Shares Authorized | 20000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Research And Development Expense | 5400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 29300000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Radiofrequency Ablation; | ||
| 0001606498-25-000091 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 10100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Corporate And Other; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Share Based Compensation | 3600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Stockholders Equity | -29500000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20250331 | Treasury Stock Common Value | 101200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Cash And Cash Equivalents At Carrying Value | 107700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 97000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Comprehensive Income Net Of Tax | -3400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Comprehensive Income Net Of Tax | 8900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Depreciation Depletion And Amortization | 11400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Earnings Per Share Basic | -0.0200 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Goodwill | 128000000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Pain Management And Recovery; | ||
| 0001606498-25-000091 | 20250331 | Goodwill | 455900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Gross Profit | 89800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Loss From Continuing Operations Per Basic Share | 0.1400 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Loss From Continuing Operations Per Diluted Share | 0.1400 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Income Tax Expense Benefit | 3100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Increase Decrease In Accounts Receivable | -8200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Liabilities Current | 165900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Long Term Debt Current | 9400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Net Cash Provided By Used In Financing Activities | -29100000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Cash Provided By Used In Investing Activities | -2000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Net Income Loss | 15400000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20240331 | Net Income Loss | -900000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20241231 | Operating Lease Liability Current | 10900000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -2200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -2500000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20240331 | Other Operating Activities Cash Flow Statement | -400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Other Operating Income Expense Net | -200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Payments For Repurchase Of Common Stock | 2200000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Payments To Acquire Productive Assets | 6700000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20241231 | Property Plant And Equipment Net | 110700000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Research And Development Expense | 7000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20240331 | Research And Development Expense | -2000000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Pain Management And Recovery; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Research And Development Expense | -4100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Specialty Nutrition Systems; Consolidation Items= Operating Segments; | ||
| 0001606498-25-000091 | 20250331 | Retained Earnings Accumulated Deficit | -700400000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001606498-25-000091 | 20231231 | Stockholders Equity | -27000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001606498-25-000091 | 20231231 | Stockholders Equity | -314900000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001606498-25-000091 | 20231231 | Stockholders Equity | -85900000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001606498-25-000091 | 20241231 | Treasury Stock Common Value | 99000000.0000 | USD | 0 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Increase Decrease In Accounts Payable Trade | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable, Trade | Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Payments To Acquire Productive Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Productive Assets | The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent | Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent. |
| Gain Loss On Disposition Of Assets1 | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Assets | Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent | Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent. |
| Other Operating Activities Cash Flow Statement | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Operating Activities, Cash Flow Statement | Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Accounts Receivable Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Gross Profit | us-gaap/2024 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | us-gaap/2024 | 0 | 0 | perShare | D | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share | Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. | |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Income Loss From Continuing Operations Per Diluted Share | us-gaap/2024 | 0 | 0 | perShare | D | Income (Loss) from Continuing Operations, Per Diluted Share | The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Interest Expense Nonoperating | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Nonoperating | Amount of interest expense classified as nonoperating. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Other Operating Income Expense Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Operating Income (Expense), Net | The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Repayments Of Secured Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Secured Debt | The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | us-gaap/2024 | 0 | 0 | perShare | D | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share | Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. | |
| Income Loss From Continuing Operations Per Basic Share | us-gaap/2024 | 0 | 0 | perShare | D | Income (Loss) from Continuing Operations, Per Basic Share | The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. | |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Proceeds From Divestiture Of Businesses | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Divestiture of Businesses | The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Income Loss From Continuing Operations | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | Amount after tax of income (loss) from continuing operations attributable to the parent. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. |
| Payments For Repurchase Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Proceeds From Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Lines of Credit | Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Investment Income Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment for Contingent Consideration Liability, Financing Activities | Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Repayments Of Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Lines of Credit | Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. |
| Treasury Stock Common Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Treasury Stock, Common, Value | Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. |
| Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Long Term Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Treasury Stock Value Acquired Cost Method | us-gaap/2024 | 0 | 0 | monetary | D | D | Treasury Stock, Value, Acquired, Cost Method | Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. |
| Payments For Proceeds From Investments In Non Affiliates | 0001606498-25-000091 | 1 | 0 | monetary | D | C | Payments for (Proceeds From) Investments In Non-Affiliates | Payments for (Proceeds From) Investments In Non-Affiliates |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001606498-25-000091 | 2 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Net Sales | 0 |
| 0001606498-25-000091 | 2 | 2 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of products sold | 0 |
| 0001606498-25-000091 | 2 | 3 | IS | 0 | H | Gross Profit | us-gaap/2024 | Gross Profit | 0 |
| 0001606498-25-000091 | 2 | 4 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001606498-25-000091 | 2 | 5 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling and general expenses | 0 |
| 0001606498-25-000091 | 2 | 6 | IS | 0 | H | Other Operating Income Expense Net | us-gaap/2024 | Other (income) expense, net | 1 |
| 0001606498-25-000091 | 2 | 7 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Operating Income | 0 |
| 0001606498-25-000091 | 2 | 8 | IS | 0 | H | Investment Income Interest | us-gaap/2024 | Interest income | 0 |
| 0001606498-25-000091 | 2 | 9 | IS | 0 | H | Interest Expense Nonoperating | us-gaap/2024 | Interest expense | 1 |
| 0001606498-25-000091 | 2 | 10 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Income Before Income Taxes | 0 |
| 0001606498-25-000091 | 2 | 11 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax provision | 1 |
| 0001606498-25-000091 | 2 | 12 | IS | 0 | H | Income Loss From Continuing Operations | us-gaap/2024 | Income from Continuing Operations | 0 |
| 0001606498-25-000091 | 2 | 13 | IS | 0 | H | Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | us-gaap/2024 | Loss from discontinued operations, net of tax | 0 |
| 0001606498-25-000091 | 2 | 14 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001606498-25-000091 | 2 | 16 | IS | 0 | H | Income Loss From Continuing Operations Per Basic Share | us-gaap/2024 | Continuing operations (in dollars per share) | 0 |
| 0001606498-25-000091 | 2 | 17 | IS | 0 | H | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | us-gaap/2024 | Discontinued operations (in dollars per share) | 0 |
| 0001606498-25-000091 | 2 | 18 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic Earnings (Loss) Per Share (in dollars per share) | 0 |
| 0001606498-25-000091 | 2 | 20 | IS | 0 | H | Income Loss From Continuing Operations Per Diluted Share | us-gaap/2024 | Continuing operations (in dollars per share) | 0 |
| 0001606498-25-000091 | 2 | 21 | IS | 0 | H | Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | us-gaap/2024 | Discontinued operations (in dollars per share) | 0 |
| 0001606498-25-000091 | 2 | 22 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted Earnings (Loss) Per Share (in dollars per share) | 0 |
| 0001606498-25-000091 | 3 | 1 | CI | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001606498-25-000091 | 3 | 3 | CI | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Unrealized currency translation adjustments | 0 |
| 0001606498-25-000091 | 3 | 4 | CI | 0 | H | Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Defined benefit plans | 1 |
| 0001606498-25-000091 | 3 | 5 | CI | 0 | H | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | us-gaap/2024 | Cash flow hedges | 0 |
| 0001606498-25-000091 | 3 | 6 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Total Other Comprehensive Income (Loss), Net of Tax | 0 |
| 0001606498-25-000091 | 3 | 7 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive Income (Loss) | 0 |
| 0001606498-25-000091 | 4 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001606498-25-000091 | 4 | 4 | BS | 0 | H | Accounts Receivable Net | us-gaap/2024 | Accounts receivable, net of allowances | 0 |
| 0001606498-25-000091 | 4 | 5 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventories | 0 |
| 0001606498-25-000091 | 4 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid and other current assets | 0 |
| 0001606498-25-000091 | 4 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total Current Assets | 0 |
| 0001606498-25-000091 | 4 | 8 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property, Plant and Equipment, net | 0 |
| 0001606498-25-000091 | 4 | 9 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating Lease Right-of-Use Assets | 0 |
| 0001606498-25-000091 | 4 | 10 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0001606498-25-000091 | 4 | 11 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Other Intangible Assets, net | 0 |
| 0001606498-25-000091 | 4 | 12 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred Tax Assets | 0 |
| 0001606498-25-000091 | 4 | 13 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other Assets | 0 |
| 0001606498-25-000091 | 4 | 14 | BS | 0 | H | Assets | us-gaap/2024 | TOTAL ASSETS | 0 |
| 0001606498-25-000091 | 4 | 17 | BS | 0 | H | Long Term Debt Current | us-gaap/2024 | Current portion of long-term debt | 0 |
| 0001606498-25-000091 | 4 | 18 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Current portion of operating lease liabilities | 0 |
| 0001606498-25-000091 | 4 | 19 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Trade accounts payable | 0 |
| 0001606498-25-000091 | 4 | 20 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0001606498-25-000091 | 4 | 21 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total Current Liabilities | 0 |
| 0001606498-25-000091 | 4 | 22 | BS | 0 | H | Long Term Debt | us-gaap/2024 | Long-Term Debt | 0 |
| 0001606498-25-000091 | 4 | 23 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating Lease Liabilities | 0 |
| 0001606498-25-000091 | 4 | 24 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | Deferred Tax Liabilities | 0 |
| 0001606498-25-000091 | 4 | 25 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other Long-Term Liabilities | 0 |
| 0001606498-25-000091 | 4 | 26 | BS | 0 | H | Liabilities | us-gaap/2024 | Total Liabilities | 0 |
| 0001606498-25-000091 | 4 | 27 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and Contingencies | 0 |
| 0001606498-25-000091 | 4 | 29 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0 |
| 0001606498-25-000091 | 4 | 30 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock - $0.01 par value - authorized 300,000,000 shares, 46,236,444 outstanding as of March 31, 2025 and 45,962,627 outstanding as of December 31, 2024 | 0 |
| 0001606498-25-000091 | 4 | 31 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001606498-25-000091 | 4 | 32 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001606498-25-000091 | 4 | 33 | BS | 0 | H | Treasury Stock Common Value | us-gaap/2024 | Treasury stock | 1 |
| 0001606498-25-000091 | 4 | 34 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0001606498-25-000091 | 4 | 35 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total Stockholders Equity | 0 |
| 0001606498-25-000091 | 4 | 36 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 0 |
| 0001606498-25-000091 | 5 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001606498-25-000091 | 5 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized (in shares) | 0 |
| 0001606498-25-000091 | 5 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001606498-25-000091 | 5 | 4 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001606498-25-000091 | 5 | 5 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001606498-25-000091 | 5 | 6 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001606498-25-000091 | 6 | 11 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0001606498-25-000091 | 6 | 12 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Exercise or redemption of share-based awards | 0 |
| 0001606498-25-000091 | 6 | 13 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001606498-25-000091 | 6 | 14 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001606498-25-000091 | 6 | 15 | EQ | 0 | H | Treasury Stock Value Acquired Cost Method | us-gaap/2024 | Purchases of treasury stock | 1 |
| 0001606498-25-000091 | 6 | 16 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Other comprehensive income (loss), net of tax | 0 |
| 0001606498-25-000091 | 6 | 17 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0001606498-25-000091 | 7 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001606498-25-000091 | 7 | 3 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001606498-25-000091 | 7 | 4 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001606498-25-000091 | 7 | 5 | CF | 0 | H | Gain Loss On Disposition Of Assets1 | us-gaap/2024 | Net loss on asset dispositions and impairments | 1 |
| 0001606498-25-000091 | 7 | 7 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0001606498-25-000091 | 7 | 8 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventories | 1 |
| 0001606498-25-000091 | 7 | 9 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other assets | 1 |
| 0001606498-25-000091 | 7 | 10 | CF | 0 | H | Increase Decrease In Accounts Payable Trade | us-gaap/2024 | Accounts payable | 0 |
| 0001606498-25-000091 | 7 | 11 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0001606498-25-000091 | 7 | 12 | CF | 0 | H | Other Operating Activities Cash Flow Statement | us-gaap/2024 | Deferred income taxes and other | 0 |
| 0001606498-25-000091 | 7 | 13 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Cash Provided by (Used in) Operating Activities | 0 |
| 0001606498-25-000091 | 7 | 15 | CF | 0 | H | Payments To Acquire Productive Assets | us-gaap/2024 | Capital expenditures | 1 |
| 0001606498-25-000091 | 7 | 16 | CF | 0 | H | Proceeds From Divestiture Of Businesses | us-gaap/2024 | Proceeds from RH Divestiture post-closing settlement | 0 |
| 0001606498-25-000091 | 7 | 17 | CF | 0 | H | Payments For Proceeds From Investments In Non Affiliates | 0001606498-25-000091 | Investments in Non-affiliates | 1 |
| 0001606498-25-000091 | 7 | 18 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Cash Used in Investing Activities | 0 |
| 0001606498-25-000091 | 7 | 20 | CF | 0 | H | Repayments Of Secured Debt | us-gaap/2024 | Secured debt repayments | 1 |
| 0001606498-25-000091 | 7 | 21 | CF | 0 | H | Proceeds From Lines Of Credit | us-gaap/2024 | Revolving credit facility proceeds | 0 |
| 0001606498-25-000091 | 7 | 22 | CF | 0 | H | Repayments Of Lines Of Credit | us-gaap/2024 | Revolving credit facility repayments | 1 |
| 0001606498-25-000091 | 7 | 23 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2024 | Purchases of treasury stock | 1 |
| 0001606498-25-000091 | 7 | 24 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options | 0 |
| 0001606498-25-000091 | 7 | 25 | CF | 0 | H | Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | Payment of contingent consideration liabilities | 1 |
| 0001606498-25-000091 | 7 | 26 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Cash Used in Financing Activities | 0 |
| 0001606498-25-000091 | 7 | 27 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0 |
| 0001606498-25-000091 | 7 | 28 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Decrease in Cash and Cash Equivalents | 0 |
| 0001606498-25-000091 | 7 | 29 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and Cash Equivalents - Beginning of Period | 0 |
| 0001606498-25-000091 | 7 | 30 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and Cash Equivalents - End of Period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |